Programmed obsolescence of medicines

While health insurer Helsana claims that only 12% of new drugs are truly innovative, several experts are denouncing the programmed obsolescence of medicines. At issue is the duration of patents, limited to 20 years, which the industry seeks to make as profitable as possible.